Cimerli Interchangeable Biosimilar Approved Without Switching Data

Coherus Ranibizumab Rival Will Compete With Lucentis And Byooviz In US

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.

Railroad tracks crossing
Coherus avoided having to conduct a study in which patients switched back and forth between Cimerli and the reference product Lucentis • Source: Shutterstock

The US Food and Drug Administration on 2 August approved Coherus BioSciences’ Cimerli (ranibizumab-eqrn) as the first interchangeable biosimilar to Genentech’s age-related macular degeneration treatment Lucentis, without the need for a “switching” study.

Cimerli is approved for all five of Lucentis’ indications: neovascular (wet) AMD; macular edema following retinal vein occlusion; diabetic macular...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

Gilead Settlements Push Back US Biktarvy Competition To 2036

 
• By 

Thanks to settlements with three generic challengers – Cipla, Laurus Labs and Lupin – Gilead says it has now kept competition to its $13bn Biktarvy brand off the US market until April 2036.

Alvotech And Advanz Celebrate EU Omalizumab Filing

 
• By 

Another European Xolair biosimilar filing has been accepted by the EMA, with partners Alvotech and Advanz submitting the Kashiv-developed omalizumab rival shortly after US commercialization counterpart Amneal lodged its own filing with the FDA.

Japan Continues Toward Self-Reliance with Alfresa-Led Biosimilars Alliance

 
• By 

Alfresa Holdings, Kidswell Bio, Chiome Bioscience, and Taiwan’s Mycenax have formed a two-track alliance to accelerate Japan’s shift to domestically produced biosimilars.

Better Late Than Never? The FDA Releases New Batch Of PSGs

 

While the latest release has twice as many PSGs compared to the previous batch, the FDA is seemingly struggling to keep up with its publication schedule.

More from Generics Bulletin

Hikma Adds Six Celltrion Biosimilars To Considerable MENA Partnership

 
• By 

Hikma has picked up the commercialization rights to half-a-dozen Celltrion biosimilars in the Middle East and North Africa, in the latest agreement between the pair.

Sandoz Canada Looks To Savings With First Entresto Rival

 
• By 

North America will enjoy further generic competition to Entresto, after Sandoz became the first company to launch a generic version of Novartis’ heart failure blockbuster in Canada.

FDA Seeks To Encourage Onshoring With ANDA Prioritization Pilot

 
• By 

The latest incentive for firms to localize production in the US will see the FDA launch a pilot program to prioritize the review of US-manufactured and tested ANDA products.